Company: TBPH
Filing Date: 2025-06-26
Form Type: 8-K
Source: 0001104659-25-062722
Chunk: 0

Company: Theravance Biopharma, Inc.
Filing Date: 2025-06-26
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

On June 26, 2025, Theravance Biopharma, Inc. (“ Theravance Biopharma”
or the “ Company”) (NASDAQ: TBPH) announced that Viatris, Inc. (“ Viatris”) has secured regulatory approval from
China’s National Medical Products Administration (NMPA) for YUPELRI®(revefenacin) inhalation solution, the first
once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease
(COPD) in China.

This
approval triggers a one-time $7.5 million milestone from Viatris to Theravance, which is expected to be received in Q3 2025. Theravance
is also eligible for further sales-based milestones and tiered royalties on net sales in China. Viatris is responsible for all aspects
of development and commercialization of YUPELRI in China.

A copy of the press release is furnished as Exhibit 99.1 to this Current
Report.

The information in this Current Report (including Exhibit 99.1)
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall
not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  99.1      Press Release dated June 26, 2025                                                                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────
   104      Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)  

SIGNATURE

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                           THERAVANCE BIOPHARMA, INC.                                                         
  Date: June 26, 2025      By:                             /s/ Aziz Sawaf                                     
                                                           Aziz Sawaf                                         
                                                           Senior Vice President and Chief Financial